Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

United Therapeutics (UTHR) Cash & Current Investments (2016 - 2025)

United Therapeutics (UTHR) has disclosed Cash & Current Investments for 17 consecutive years, with $2.9 billion as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments fell 10.61% to $2.9 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2.9 billion through Dec 2025, down 10.61% year-over-year, with the annual reading at $2.9 billion for FY2025, 10.61% down from the prior year.
  • Cash & Current Investments hit $2.9 billion in Q4 2025 for United Therapeutics, up from $2.8 billion in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $3.3 billion in Q3 2024 to a low of $1.7 billion in Q1 2021.
  • Historically, Cash & Current Investments has averaged $2.7 billion across 5 years, with a median of $2.8 billion in 2022.
  • Biggest five-year swings in Cash & Current Investments: surged 47.03% in 2022 and later dropped 16.8% in 2025.
  • Year by year, Cash & Current Investments stood at $1.9 billion in 2021, then skyrocketed by 47.03% to $2.8 billion in 2022, then grew by 5.47% to $3.0 billion in 2023, then increased by 9.11% to $3.3 billion in 2024, then fell by 10.61% to $2.9 billion in 2025.
  • Business Quant data shows Cash & Current Investments for UTHR at $2.9 billion in Q4 2025, $2.8 billion in Q3 2025, and $3.0 billion in Q2 2025.